Oncohost

OncohostOncohost
Oncohost

Oncohost

Leveraging proteomic pattern analysis to personalize cancer treatment and improve patient outcomes.

Website
2017Active46Tel Aviv, Israel
Rate
Advertise here

About

OncoHost's PROphet® platform uses bioinformatic proteomic pattern recognition and AI to generate a personalized PROphet® score, predicting the benefit of PD-1/PD-L1 inhibitors. This blood-based test provides an all-inclusive evaluation of the tumor and host microenvironment to aid clinical decision-making and improve patient outcomes. The company serves patients, providers, and pharmaceutical partners.

Technology stack

detected 2026-07-09
CDN
Email
Stack
Video
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Oncohost do?

OncoHost's PROphet® platform uses bioinformatic proteomic pattern recognition and AI to generate a personalized PROphet® score, predicting the benefit of PD-1/PD-L1 inhibitors. This blood-based test provides an all-inclusive evaluation of the tumor and host microenvironment to aid clinical decision-making and improve patient outcomes. The company serves patients, providers, and pharmaceutical partners.

How much funding has Oncohost raised?

Oncohost has raised a total of $43M in funding. The most recent round on record is Series C.

Where is Oncohost headquartered?

Oncohost is headquartered in Tel Aviv, Israel.

When was Oncohost founded?

Oncohost was founded in 2017.

What industry does Oncohost operate in?

Oncohost operates in Healthcare, Pharmaceutical, Oncology, Cancer, Proteomics, HealthTech.

How many employees does Oncohost have?

Oncohost has approximately 46 people on record.

What is Oncohost's revenue?

StartupHub estimates Oncohost's annual revenue at $15.7M (range $8.5M to $26.1M, 63% confidence), based on comparable companies in the sector.

What is Oncohost's valuation?

StartupHub estimates Oncohost's effective valuation at $174.5M (range $107.5M to $258.0M, 10% confidence), based on comparable companies in the sector.